You are here

Xarelto

Rivaroxaban reduces adverse kidney events in atrial fibrillation patients with CKD

Rivaroxaban reduces adverse kidney events in atrial fibrillation patients with CKD

Clinical Trials Arena

real world data

atrial fibrillation

Flag link:

ESC 2022 preview – who’s got the XI factor?

ESC 2022 preview – who’s got the XI factor?

EP Vantage

Bristol Myers Squibb

Flag link:

Did J&J and BMS conspire on blood thinner price hikes? Congressional leaders want DOJ, FTC to look into it: report

Did J&J and BMS conspire on blood thinner price hikes? Congressional leaders want DOJ, FTC to look into it: report

Fierce Pharma

Bristol Myers Squibb

Flag link:

With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?

With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?

Fierce Pharma

Flag link:

J&J, Bayer's Xarelto scores FDA nod in post-surgery artery disease as partners try to catch up with Eliquis

J&J, Bayer's Xarelto scores FDA nod in post-surgery artery disease as partners try to catch up with Eliquis

Fierce Pharma

Bristol Myers Squibb

Flag link:

ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients

ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients

Fierce Pharma

Flag link:

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it's better than expected

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it's better than expected

Fierce Pharma

Flag link:

ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study

ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study

Fierce Pharma

Bristol-Myers Squibb

site-specific bleeding

Flag link:

ACC: J&J, Bayer's blood thinner Xarelto scores in artery disease post-surgery

ACC: J&J, Bayer's blood thinner Xarelto scores in artery disease post-surgery

Fierce Pharma

clinical trials

peripheral artery disease

Flag link:

J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER

J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER

Endpoints

Flag link:

FDA OKs new use for J&J's Xarelto

FDA OKs new use for J&J's Xarelto

Seeking Alpha

venous thromboembolism

Flag link:

Xarelto falls into the donut hole

Xarelto falls into the donut hole

Biopharma Dive

Flag link:

J&J Takes Hits on Talc Lawsuit, Settles Xarelto Suit, Faces Pricing Criticism

J&J Takes Hits on Talc Lawsuit, Settles Xarelto Suit, Faces Pricing Criticism

BioSpace

Flag link:

Bayer, J&J's Xarelto scripts stagnate as discounts, competition pile up

Bayer, J&J's Xarelto scripts stagnate as discounts, competition pile up

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Price checked: J&J launches industry-first TV ad with drug list price

Price checked: J&J launches industry-first TV ad with drug list price

Fierce Biotech

Flag link:

Bayer and J&J settle Xarelto lawsuits in US

Bayer and J&J settle Xarelto lawsuits in US

Pharmaforum

Flag link:

With Bayer predicting slowdowns for Xarelto and Eylea, what will fill the gap?

With Bayer predicting slowdowns for Xarelto and Eylea, what will fill the gap?

Fierce Pharma

Flag link:

Discounting hit J&J's Xarelto hard. Can a new launch turn things around?

Discounting hit J&J's Xarelto hard. Can a new launch turn things around?

Fierce Pharma

Flag link:

J&J snaps up key label expansion for Xarelto

J&J snaps up key label expansion for Xarelto

Biopharma Dive

Flag link:

ESC 2018 – J&J not downhearted after Xarelto stumbles

ESC 2018 – J&J not downhearted after Xarelto stumbles

EP Vantage

Flag link:

Pages